Role of receptor occupancy assays by flow cytometry in drug development.

about

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.Analytical considerations for quantitative LC-MS strategies for measuring antibody drug-target engagement in tissues.Highlights - June 2017.

P2860

Q47113773-461590C5-21E4-4D8E-A8E4-6B3537A8A334 Q49679487-1F185F0D-243A-4BCD-9B71-A4590B999E01 Q54198759-B8FB92AF-4027-418B-8455-CD4D701282DF

P2860

Role of receptor occupancy assays by flow cytometry in drug development.

Item

http://www.wikidata.org/entity/Q38679593

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Role of receptor occupancy assays by flow cytometry in drug development.

@en

type

Item

label

Role of receptor occupancy assays by flow cytometry in drug development.

@en

prefLabel

Role of receptor occupancy assays by flow cytometry in drug development.

@en

P1476

Role of receptor occupancy assays by flow cytometry in drug development.

@en

P2093

Alan Lackey

http://www.w3.org/2001/XMLSchema#string

Barry W A van der Strate

http://www.w3.org/2001/XMLSchema#string

Carl-Magnus Högerkorp

http://www.w3.org/2001/XMLSchema#string

Cherie L Green

http://www.w3.org/2001/XMLSchema#string

Danice E C Wilkins

http://www.w3.org/2001/XMLSchema#string

David Lanham

http://www.w3.org/2001/XMLSchema#string

Jennifer J Stewart

http://www.w3.org/2001/XMLSchema#string

John Ferbas

http://www.w3.org/2001/XMLSchema#string

Kamila Czechowska

http://www.w3.org/2001/XMLSchema#string

Maxime Moulard

http://www.w3.org/2001/XMLSchema#string

P2860

Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.

Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection

Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.

The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer

P304

110-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CYTO.B.21355

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26704557

http://www.w3.org/2001/XMLSchema#string

Role of receptor occupancy assays by flow cytometry in drug development.

about

P2860

P2860

Role of receptor occupancy assays by flow cytometry in drug development.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698